Literature DB >> 24525553

A comparison of left ventricular endocardial, multisite, and multipolar epicardial cardiac resynchronization: an acute haemodynamic and electroanatomical study.

Anoop K Shetty1, Manav Sohal2, Zhong Chen2, Matthew R Ginks2, Julian Bostock3, Sana Amraoui2, Kyungmoo Ryu4, Stuart P Rosenberg4, Steven A Niederer5, Jas Gill2, Gerry Carr-White2, Reza Razavi5, C Aldo Rinaldi2.   

Abstract

AIMS: Alternative forms of cardiac resynchronization therapy (CRT), including biventricular endocardial (BV-Endo) and multisite epicardial pacing (MSP), have been developed to improve response. It is unclear which form of stimulation is optimal. We aimed to compare the acute haemodynamic response (AHR) and electrophysiological effects of BV-Endo with MSP via two separate coronary sinus (CS) leads or a single-quadripolar CS lead. METHODS AND
RESULTS: Fifteen patients with a previously implanted CRT system received a second temporary CS lead and left ventricular (LV) endocardial catheter. A pressure wire and non-contact mapping array were placed into the LV cavity to measure LVdP/dtmax and perform electroanatomical mapping. Conventional CRT, BV-Endo, and MSP were then performed (MSP-1 via two epicardial leads and MSP-2 via a single-quadripolar lead). The best overall AHR was found using BV-Endo pacing with a 19.6 ± 13.6% increase in AHR at the optimal endocardial site over baseline (P < 0.001). There was an increase in LVdP/dtmax with MSP-1 and MSP-2 compared with conventional CRT, but this was not statistically significant. Biventricular endocardial pacing from the optimal site was significantly superior to conventional CRT (P = 0.039). The AHR achieved when BV-Endo pacing was highly site specific. Within individuals, the best pacing modality varied and was affected by the underlying substrate. Left ventricular activation times did not predict the optimal haemodynamic configuration.
CONCLUSION: Biventricular endocardial pacing and not MSP was superior to conventional CRT, but was highly site specific. Within individuals, however, different methods of stimulation are optimal and may need to be tailored to the underlying substrate. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiac resynchronization therapy; Electrophysiology mapping; Haemodynamics; Multisite pacing

Mesh:

Year:  2014        PMID: 24525553     DOI: 10.1093/europace/eut420

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  23 in total

Review 1.  Multisite pacing via a quadripolar lead for cardiac resynchronization therapy.

Authors:  Alexandre Bodin; Arnaud Bisson; Clémentine Andre; Bertrand Pierre; Laurent Fauchier; Dominique Babuty; Nicolas Clementy
Journal:  J Interv Card Electrophysiol       Date:  2019-07-18       Impact factor: 1.900

Review 2.  Multisite Pacing for Cardiac Resynchronization Therapy: Promise and Pitfalls.

Authors:  Antonios P Antoniadis; Jonathan M Behar; Simon Claridge; Tom Jackson; Manav Sohal; Christopher Aldo Rinaldi
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

Review 3.  Cardiac Resynchronization Therapy-Emerging Therapeutic Approaches.

Authors:  Neal A Chatterjee; E Kevin Heist
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-06

4.  The effect of left ventricular pacing on transmural activation delay in myopathic human hearts.

Authors:  Andreu Porta-Sánchez; Paul Angaran; Stéphane Massé; Krishnakumar Nair; Talha Farid; Karthikeyan Umapathy; John Asta; Sigfus Gizurarson; Kumaraswamy Nanthakumar
Journal:  Europace       Date:  2018-04-01       Impact factor: 5.214

5.  Rationale and design of a randomized trial to assess the safety and efficacy of MultiPoint Pacing (MPP) in cardiac resynchronization therapy: The MPP Trial.

Authors:  Gery Tomassoni; James Baker; Raffaele Corbisiero; Charles Love; David Martin; Robert Sheppard; Seth J Worley; Kwangdeok Lee; Imran Niazi
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05-18       Impact factor: 1.468

6.  Evaluating multisite pacing strategies in cardiac resynchronization therapy in the preclinical setting.

Authors:  Luuk I B Heckman; Marion Kuiper; Frederic Anselme; Filippo Ziglio; Nicolas Shan; Markus Jung; Stef Zeemering; Kevin Vernooy; Frits W Prinzen
Journal:  Heart Rhythm O2       Date:  2020-06-15

7.  Effects of Epicardial and Endocardial Cardiac Resynchronization Therapy on Coronary Flow: Insights From Wave Intensity Analysis.

Authors:  Simon Claridge; Zhong Chen; Tom Jackson; Kalpa De Silva; Jonathan Behar; Manav Sohal; Jessica Webb; Eoin Hyde; Matthew Lumley; Kal Asrress; Rupert Williams; Julian Bostock; Motin Ali; Jaswinder Gill; Mark O'Neill; Reza Razavi; Steve Niederer; Divaka Perera; Christopher Aldo Rinaldi
Journal:  J Am Heart Assoc       Date:  2015-12-17       Impact factor: 5.501

8.  In Heart Failure Patients with Left Bundle Branch Block Single Lead MultiSpot Left Ventricular Pacing Does Not Improve Acute Hemodynamic Response To Conventional Biventricular Pacing. A Multicenter Prospective, Interventional, Non-Randomized Study.

Authors:  Maciej Sterliński; Adam Sokal; Radosław Lenarczyk; Frederic Van Heuverswyn; C Aldo Rinaldi; Marc Vanderheyden; Vladimir Khalameizer; Darrel Francis; Joeri Heynens; Berthold Stegemann; Richard Cornelussen
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

9.  The impact of beat-to-beat variability in optimising the acute hemodynamic response in cardiac resynchronisation therapy.

Authors:  Steven Niederer; Cameron Walker; Andrew Crozier; Eoin R Hyde; Bojan Blazevic; Jonathan M Behar; Simon Claridge; Manav Sohal; Anoop Shetty; Tom Jackson; Christopher Rinaldi
Journal:  Clin Trials Regul Sci Cardiol       Date:  2015-12

10.  Haemodynamic evaluation of alternative left ventricular endocardial pacing sites in clinical non-responders to cardiac resynchronisation therapy.

Authors:  B M van Gelder; R Nathoe; F A Bracke
Journal:  Neth Heart J       Date:  2016-01       Impact factor: 2.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.